Guías

Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 

Área: Lípidos
Año: 2019

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

Área: Lípidos
Año: 2019
URL: https://doi.org/10.1093/eurheartj/ehab551
Referencia: Eur Heart J. 2021; 42:4791-4806

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019-

Área: Lípidos
Año: 2019
URL: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-indicaciones-inhibidores-pcsk9-practica-clinica–S0214916819300518
Referencia: Clin Invest Arterioescler 2019; 31:128-139.

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Área: Lípidos
Año: 2019
URL: https://doi.org/10.1093/eurheartj/ehac361
Referencia: Eur Heart J 2022; 43: 3925-3946

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Área: Lípidos
Año: 2019
URL: https://www.jacc.org/doi/10.1016/j.jacc.2022.07.00.
Referencia: J Am Coll      Cardiol. 2022; 80:1366-1418.